Cue Biopharma reports a Q2 GAAP EPS of -$24.14, missing estimates, while revenue jumps 167.1% year-over-year to $7.88M.
Cue Biopharma reported a Q2 GAAP loss per share of -$24.14, significantly wider than expected, as the company missed estimates by $22.23. The loss reflects ongoing investment in its pipeline and operational costs.
Revenue for the quarter reached $7.88 million, beating expectations by $5.78 million and marking a 167.1% increase year-over-year. The company attributed the revenue growth to milestone payments and collaboration agreements. As of June 30, 2026, Cue Biopharma held $17.4 million in cash and equivalents after one-time outflows tied to a license deal.
The results highlight the company’s expanding partnerships but underscore continued financial pressure from development-stage spending.